CDMO Capabilities Peregrine operates in-house cGMP manufacturing via its subsidiary Avid Bioservices, offering development and biomanufacturing services. This presents cross-selling opportunities for contract manufacturing, process development, and scale-up projects with other biotech and pharma firms seeking reliable CDMO support.

Monoclonal Focus Lead immunotherapy program bavituximab in multiple cancer indications suggests potential for collaboration in antibody development, diagnostic imaging partnerships, and companion diagnostics opportunities aligned with oncology pipelines.

Clinical Momentum SUNRISE Phase III in second-line non-small cell lung cancer indicates ongoing large-scale trial activity and potential demand for late-stage manufacturing capacity, covert biomarkers, and trial supply services for oncology assets.

Imaging Innovation Interest in an imaging agent for cancer could open partnerships around theranostics, radiolabeled antibody programs, and diagnostic collaborations with imaging device or pharmaceutical companies seeking integrated diagnostic-therapeutic solutions.

Financial Profile Revenue range and small reporting footprint (10–25M revenue; modest funding) imply a growing but lean organization with appetite for strategic collaborations, licensing deals, and external manufacturing contracts to accelerate pipeline development while managing capital efficiency.